Melanotan I is the rare research-scene peptide that is actually an approved medicine. In its pharmaceutical form — afamelanotide, brand name Scenesse — the US FDA approved it in 2019 to help people with a rare inherited disease spend more pain-free time in sunlight2. It works by copying a natural hormone that tells skin to make more of its dark, protective pigment. The crucial thing to get right: Melanotan I is not Melanotan II, and its approval is for a specific medical condition — not for cosmetic tanning.
In plain terms: this one is a real, approved drug for a rare disease — and it is a different molecule from the "Melanotan II" people confuse it with.
What it is
Your skin colour is set partly by a hormone called α-MSH (alpha-melanocyte-stimulating hormone). When α-MSH lands on a receptor called MC1R on pigment cells, it tells them to produce eumelanin — the dark brown-black pigment that also absorbs and blocks some harmful light1.
Melanotan I is a lab-made analog of α-MSH: a 13-amino-acid peptide engineered to do the same job, but to last longer than the natural hormone (which the body breaks down within minutes). As a medicine it is called afamelanotide.
In plain terms: it is a longer-lasting copy of the body's own "make more pigment" signal.
How it works
Afamelanotide is a melanocortin-1 receptor (MC1R) agonist — "agonist" meaning it switches the receptor on2. Activating MC1R drives skin cells to build more eumelanin. More eumelanin means more natural light absorption in the skin.
That is exactly why it helps in erythropoietic protoporphyria (EPP). EPP is a rare inherited disease in which a light-sensitive molecule builds up; sunlight triggers severe burning pain in the skin, sometimes within minutes. By boosting protective pigment, afamelanotide lets people with EPP tolerate more light before pain starts1.
Pharmacokinetics and how it is given
Native α-MSH is cleared in minutes. Afamelanotide is engineered to resist that rapid breakdown, but the bigger design trick is the delivery system: it is formulated as a small bioresorbable implant placed under the skin, which slowly releases the peptide over days2. The approved regimen studied is one 16 mg implant roughly every two months, placed by a trained clinician during high-sunlight periods — a slow-release depot rather than a daily shot.
In plain terms: the peptide alone would clear quickly, so it is packaged as a slow-dissolving pellet that trickles it out over weeks.
Melanotan I vs Melanotan II — do not confuse them
This is the most important safety distinction on the page.
| Melanotan I (afamelanotide) | Melanotan II | |
|---|---|---|
| What it is | 13-amino-acid α-MSH analog | Smaller cyclic melanocortin analog |
| Main receptor | Mostly MC1R (pigment) | Several melanocortin receptors (MC1R, MC3R, MC4R) |
| Extra effects | Pigment-focused | Also appetite and sexual-function effects (via MC4R) |
| Approval | FDA-approved (Scenesse, EPP) | Not approved anywhere |
| Reputation | Regulated medicine | Linked to nausea, blood-pressure changes, and mole/pigment concerns in reports |
In plain terms: Melanotan I is the narrow, approved one; Melanotan II is the broader, unapproved one with a rougher safety record. They are not interchangeable.
What the studies actually found
The evidence here is unusually solid for a "research peptide," because afamelanotide went through the real approval process. Note the model — these are human trials:
| Study | Model / level | Key result | Year |
|---|---|---|---|
| Langendonk et al. — phase 31 | Human (EPP patients) | Afamelanotide increased pain-free time in direct sunlight vs placebo and improved quality of life | 2015 |
| FDA approval — Scenesse2 | Regulatory (human trial base) | Approved to increase pain-free light exposure in adults with EPP; based on 3 randomized vehicle-controlled trials in 244 adults | 2019 |
The pattern: a genuine, regulator-reviewed human evidence base — for one specific rare disease. That is the honest boundary of what "approved" covers here.
The honest limits
Approved does not mean approved-for-everything. Afamelanotide is cleared only for EPP, and only to increase pain-free light exposure — not as a cosmetic tan enhancer, and not for the general public. Its long-term effect on skin-cancer risk is monitored precisely because it changes pigmentation and sun behaviour. And everything above concerns the pharmaceutical implant given by clinicians — not injectable "Melanotan" products sold in the research-peptide market, which are unregulated and often confused with Melanotan II.
This page explains what Melanotan I is and what its trials showed — not how to use it — and it takes no position on sourcing.
Latest research
- The 2015 NEJM phase-3 trial remains the pivotal human evidence: more pain-free sunlight and better quality of life for EPP patients on afamelanotide1.
- The 2019 FDA approval made it one of the very few melanocortin peptides to become a regulated medicine, via a slow-release implant2.
- Newer oral MC1R agonists for EPP (a different molecule, dersimelagon/MT-7117) have since been in trials — a sign the melanocortin-for-EPP approach is expanding beyond the implant.
The short version
Melanotan I, as afamelanotide (Scenesse), is a genuinely FDA-approved melanocortin peptide — but only for the rare light-sensitivity disease EPP, given as a clinician-placed implant to increase pain-free sun time12. It is a different, more targeted molecule than the unapproved Melanotan II, and it is not approved as a cosmetic tanner. Educational overview only, not medical advice. For context, see what are research peptides.